Filing Flows › Maxcyte (MXCT) › Q2 2026
Maxcyte (MXCT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Maxcyte (MXCT) reported revenue of $7.3M for the second quarter 2026 (Q2 2026), -15% from a year earlier and -25% from the quarter before. Operating margin was -140.7%, net loss $8.9M (122.0% of revenue).
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.3M | -25% | -15% |
| Operating profit | −$10.2M | — | — |
| Net earnings | −$8.9M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $7.3M in Q2 2026, down 15% year over year and down 25% from the previous quarter. Product sales was the largest line at 56% of revenue. Product sales lost $1.2M year over year (down 22%), 95% of the total change.
Gross margin was 77.0%, down 5.2 points from Q2 2025. Operating costs exceeded revenue by $10.2M, an operating margin of -140.7%. Operating expenses fell 25% while revenue fell 15%. The quarter ended with a net loss of $8.9M, wider than the previous quarter's $4.8M loss.
Operating cash flow was −$4.7M. Non-cash charges added back $1.0M of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items added $2.1M. Capital expenditures of $62K exceeded it, leaving free cash flow of −$4.7M.
Questions
What was Maxcyte's revenue in the second quarter 2026?
Maxcyte (MXCT) reported revenue of $7.3M for the second quarter 2026 (Q2 2026), -15% from a year earlier and -25% from the quarter before.
Was Maxcyte profitable in the second quarter 2026?
Operating loss was $10.2M (-140.7% of revenue) and net loss $8.9M.
Source: Maxcyte 10-Q on SEC EDGAR.